EP 3589646 A4 20210120 - CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
Title (en)
CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
Title (de)
CD19-ZUSAMMENSETZUNGEN UND VERFAHREN FÜR DIE IMMUNTHERAPIE
Title (fr)
COMPOSITIONS À BASE DE CD19 ET MÉTHODES POUR L'IMMUNOTHÉRAPIE
Publication
Application
Priority
- US 201762466601 P 20170303
- US 201762484052 P 20170411
- US 2018020741 W 20180302
Abstract (en)
[origin: WO2018161017A1] The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.
IPC 8 full level
C12N 9/06 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 35/00 (2006.01); A61K 35/14 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 9/02 (2006.01); C12N 9/64 (2006.01); C12N 15/62 (2006.01)
CPC (source: EP KR)
A61K 31/505 (2013.01 - EP KR); A61K 31/519 (2013.01 - EP KR); A61K 35/14 (2013.01 - EP KR); A61K 38/164 (2013.01 - KR); A61K 38/1709 (2013.01 - KR); A61K 38/177 (2013.01 - KR); A61K 38/208 (2013.01 - KR); A61K 38/2086 (2013.01 - KR); A61K 39/39 (2013.01 - EP); A61K 39/4611 (2023.05 - EP KR); A61K 39/4631 (2023.05 - EP KR); A61K 39/464412 (2023.05 - EP KR); A61K 45/06 (2013.01 - KR); A61P 35/00 (2018.01 - EP KR); C07K 14/70503 (2013.01 - EP KR); C07K 14/7051 (2013.01 - KR); C07K 16/2803 (2013.01 - EP KR); C07K 16/3061 (2013.01 - EP KR); C12N 9/003 (2013.01 - EP KR); C12N 9/90 (2013.01 - KR); G01N 33/6845 (2013.01 - KR); A61K 38/00 (2013.01 - EP KR); A61K 2039/804 (2018.08 - EP KR); A61K 2239/31 (2023.05 - EP KR); A61K 2239/48 (2023.05 - EP KR); A61K 2239/49 (2023.05 - EP KR); A61K 2239/57 (2023.05 - EP KR); C07K 14/7051 (2013.01 - EP); C07K 2317/622 (2013.01 - EP KR); C07K 2317/92 (2013.01 - EP KR); C07K 2319/03 (2013.01 - EP KR); C07K 2319/20 (2013.01 - EP KR); C07K 2319/33 (2013.01 - EP KR); G01N 2333/705 (2013.01 - KR); Y02A 50/30 (2018.01 - EP)
Citation (search report)
- [A] US 2014010791 A1 20140109 - WANDLESS THOMAS J [US], et al
- [AD] US 8173792 B2 20120508 - WANDLESS THOMAS J [US], et al
- [E] WO 2018231759 A1 20181220 - OBSIDIAN THERAPEUTICS INC [US]
- [A] ALEXANDRE JUILLERAT ET AL: "Design of chimeric antigen receptors with integrated controllable transient functions", SCIENTIFIC REPORTS, vol. 6, 11 January 2016 (2016-01-11), pages 18950, XP055271820, DOI: 10.1038/srep18950
- See also references of WO 2018161017A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018161017 A1 20180907; AU 2018227583 A1 20191017; AU 2018227583 B2 20230601; AU 2023214349 A1 20230831; CA 3055202 A1 20180907; CN 110831961 A 20200221; CN 110831961 B 20240102; EP 3589646 A1 20200108; EP 3589646 A4 20210120; JP 2020511529 A 20200416; JP 2023164900 A 20231114; JP 7341900 B2 20230911; KR 20200010181 A 20200130; SG 10202001869V A 20200429; SG 11201907922P A 20190927
DOCDB simple family (application)
US 2018020741 W 20180302; AU 2018227583 A 20180302; AU 2023214349 A 20230811; CA 3055202 A 20180302; CN 201880025103 A 20180302; EP 18760420 A 20180302; JP 2019568594 A 20180302; JP 2023139792 A 20230830; KR 20197029002 A 20180302; SG 10202001869V A 20180302; SG 11201907922P A 20180302